CN117751195A - 脓毒症内型和/或严重程度的诊断 - Google Patents
脓毒症内型和/或严重程度的诊断 Download PDFInfo
- Publication number
- CN117751195A CN117751195A CN202280052217.XA CN202280052217A CN117751195A CN 117751195 A CN117751195 A CN 117751195A CN 202280052217 A CN202280052217 A CN 202280052217A CN 117751195 A CN117751195 A CN 117751195A
- Authority
- CN
- China
- Prior art keywords
- endotype
- signature
- sepsis
- lgals3bp
- fech
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192746P | 2021-05-25 | 2021-05-25 | |
| US63/192,746 | 2021-05-25 | ||
| PCT/CA2022/050831 WO2022246553A1 (en) | 2021-05-25 | 2022-05-25 | Diagnostic for sepsis endotypes and/or severity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117751195A true CN117751195A (zh) | 2024-03-22 |
Family
ID=84229117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280052217.XA Pending CN117751195A (zh) | 2021-05-25 | 2022-05-25 | 脓毒症内型和/或严重程度的诊断 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240254557A1 (enExample) |
| EP (1) | EP4352250A4 (enExample) |
| JP (1) | JP2024520049A (enExample) |
| CN (1) | CN117751195A (enExample) |
| AU (1) | AU2022283025A1 (enExample) |
| CA (1) | CA3221576A1 (enExample) |
| WO (1) | WO2022246553A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118389664A (zh) * | 2024-04-24 | 2024-07-26 | 南方医科大学深圳医院 | 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法 |
| CN118621011A (zh) * | 2024-06-18 | 2024-09-10 | 广东医科大学附属医院 | circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用 |
| CN120939040A (zh) * | 2025-10-20 | 2025-11-14 | 四川省医学科学院·四川省人民医院 | GYG1 siRNA在制备治疗脓毒症的药物中的应用 |
| CN122283150A (zh) * | 2026-05-29 | 2026-06-26 | 浙江省肿瘤医院 | 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用 |
| CN122283150B (zh) * | 2026-05-29 | 2026-08-21 | 浙江省肿瘤医院 | 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024148050A2 (en) * | 2023-01-04 | 2024-07-11 | Ampel Biosolutions, Llc | Longitudinal gene expression analysis of inflammatory skin diseases |
| EP4766855A1 (en) * | 2023-08-22 | 2026-07-01 | Ramot at Tel-Aviv University Ltd. | SYSTEMIC RESISTANCE AND INFLAMMATION MARKERS AND THEIR USES |
| WO2025090733A1 (en) * | 2023-10-27 | 2025-05-01 | Sanofi | Identifying disease subtypes |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| JP2008538007A (ja) | 2005-04-15 | 2008-10-02 | ベクトン,ディッキンソン アンド カンパニー | 敗血症の診断 |
| DE102005050933A1 (de) * | 2005-10-21 | 2007-04-26 | Justus-Liebig-Universität Giessen | Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen |
| US20110076685A1 (en) | 2009-09-23 | 2011-03-31 | Sirs-Lab Gmbh | Method for in vitro detection and differentiation of pathophysiological conditions |
| US20110312521A1 (en) | 2010-06-17 | 2011-12-22 | Baylor Research Institute | Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases |
| EP2834638B1 (en) | 2012-04-02 | 2020-02-12 | Astute Medical, Inc. | Methods for diagnosis and prognosis of sepsis |
| EP3013985A4 (en) | 2013-06-28 | 2017-07-19 | Acumen Research Laboratories Pte. Ltd. | Sepsis biomarkers and uses thereof |
| WO2015117204A1 (en) * | 2014-02-06 | 2015-08-13 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits therefor |
| CA2942577A1 (en) | 2014-03-14 | 2015-09-17 | Robert E. W. Hancock | Diagnostic for sepsis |
| CN107532214B (zh) | 2015-03-12 | 2021-08-31 | 斯坦福大学托管董事会 | 用于败血症诊断的方法 |
| GB201518597D0 (en) * | 2015-10-20 | 2015-12-02 | Univ Liverpool | Detection of bacterial infection |
| US11104953B2 (en) * | 2016-05-13 | 2021-08-31 | Children's Hospital Medical Center | Septic shock endotyping strategy and mortality risk for clinical application |
| KR101929772B1 (ko) * | 2016-11-02 | 2018-12-17 | 연세대학교 산학협력단 | 패혈증 진단을 위한 정보를 제공하는 방법 및 이를 이용한 키트 |
| WO2018146162A1 (en) * | 2017-02-07 | 2018-08-16 | Academisch Medisch Centrum | Molecular biomarker for prognosis of sepsis patients |
| US12571044B2 (en) * | 2018-02-27 | 2026-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Classifier for identification of robust sepsis subtypes |
| US20210388443A1 (en) * | 2018-11-05 | 2021-12-16 | Institute For Systems Biology | Sepsis biomarker panels and methods of use |
-
2022
- 2022-05-25 CN CN202280052217.XA patent/CN117751195A/zh active Pending
- 2022-05-25 JP JP2023573024A patent/JP2024520049A/ja active Pending
- 2022-05-25 WO PCT/CA2022/050831 patent/WO2022246553A1/en not_active Ceased
- 2022-05-25 AU AU2022283025A patent/AU2022283025A1/en active Pending
- 2022-05-25 US US18/563,344 patent/US20240254557A1/en active Pending
- 2022-05-25 EP EP22810003.8A patent/EP4352250A4/en active Pending
- 2022-05-25 CA CA3221576A patent/CA3221576A1/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118389664A (zh) * | 2024-04-24 | 2024-07-26 | 南方医科大学深圳医院 | 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法 |
| CN118621011A (zh) * | 2024-06-18 | 2024-09-10 | 广东医科大学附属医院 | circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用 |
| CN118621011B (zh) * | 2024-06-18 | 2025-08-29 | 广东医科大学附属医院 | circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用 |
| CN120939040A (zh) * | 2025-10-20 | 2025-11-14 | 四川省医学科学院·四川省人民医院 | GYG1 siRNA在制备治疗脓毒症的药物中的应用 |
| CN122283150A (zh) * | 2026-05-29 | 2026-06-26 | 浙江省肿瘤医院 | 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用 |
| CN122283150B (zh) * | 2026-05-29 | 2026-08-21 | 浙江省肿瘤医院 | 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022283025A1 (en) | 2024-01-18 |
| EP4352250A4 (en) | 2026-07-01 |
| CA3221576A1 (en) | 2022-12-01 |
| US20240254557A1 (en) | 2024-08-01 |
| EP4352250A1 (en) | 2024-04-17 |
| WO2022246553A1 (en) | 2022-12-01 |
| JP2024520049A (ja) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12473597B2 (en) | Methods and systems for processing a nucleic acid sample | |
| AU2020201564B2 (en) | Diagnostic for sepsis | |
| US20240254557A1 (en) | Diagnostic for sepsis endotypes and/or severity | |
| KR102461014B1 (ko) | 폐암 상태를 평가하는 방법 | |
| EP3103046B1 (en) | Biomarker signature method, and apparatus and kits therefor | |
| US11091809B2 (en) | Molecular diagnostic test for cancer | |
| US20240309469A1 (en) | Methods to detect and treat a fungal infection | |
| US20170088902A1 (en) | Expression profiling for cancers treated with anti-angiogenic therapy | |
| US20250084480A1 (en) | Methods of treating eosinophilic colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |